Skip to content
Peptigraph home

Is Semaglutide Legal? FDA, Compounding and WADA Status

Semaglutide's FDA status, compounding rules and anti-doping status, with a dated timeline of every change we track.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureGLP-1 agonistUpdated
FDA status
Approved (Ozempic, Wegovy, Rybelsus)
PCAC vote
Not reviewed
not on the Jul 2026 PCAC agenda
WADA
Not listed
2026 Prohibited List
Not legal adviceStatus reflects public FDA and WADA records on the date shown. Rules differ by country and state.

Current status

FDA approved (Ozempic, Wegovy, Rybelsus)

Semaglutide is FDA approved (Ozempic, Wegovy, Rybelsus). Products sold as research chemicals are not the approved drug and are not checked by the FDA.

Semaglutide: regulatory status by country
CountryStatusSource
United StatesApprovedApproved by FDA as Ozempic (2017), Rybelsus (2019) and Wegovy (2021), semaglutide, Novo Nordisk. Ozempic is indicated for type 2 diabetes; Wegovy for weight reduction and cardiovascular risk reduction (see label quotes). Drugs@FDA also lists a tentatively approved generic semaglutide application (Apotex, 7 Apr 2026).api.fda.govchecked 2 Oct 2026

Timeline

  1. FDA warning letters to five research-peptide sellersEnforcement
  2. FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA
  3. Seven FDA warning letters to online sellers of GLP-1 productsEnforcement
Every peptide on the FDA tracker

Compounding and research-use sellers

  • Category 2 is the FDA's list of bulk substances it flagged as raising significant safety concerns. Compounding pharmacies are not expected to compound from them while they are on it.
  • The Pharmacy Compounding Advisory Committee (PCAC) advises the FDA on which substances belong on the 503A bulks list that pharmacies may compound from. Its votes are advice; the FDA decides.
  • "Research use only" products are sold outside these rules and are not checked by the FDA for identity, purity or dose.

Sport and drug testing

Not on the WADA Prohibited List

GLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it.

Outside the US

Rules differ by country. What each regulator's own records show, with the date we checked:

Semaglutide: regulatory status by country
CountryStatusSource
United KingdomApprovedListed on emc as Ozempic, Wegovy and Rybelsus (semaglutide), Novo Nordisk Limited.medicines.org.ukchecked 2 Oct 2026
CanadaApprovedHealth Canada DPD lists Wegovy and Rybelsus (semaglutide) as Marketed; Ozempic is also listed.health-products.canada.cachecked 2 Oct 2026
AustraliaApprovedRegistered in the ARTG (TGA search for "semaglutide" on 2 Oct 2026).tga.gov.auchecked 2 Oct 2026
European UnionApprovedCentrally authorised in the EU as Wegovy, Ozempic and Rybelsus (semaglutide).ema.europa.euchecked 2 Oct 2026

Approved forms: injections, tablets and a new Wegovy pill

Drugs@FDA lists 6 semaglutide applications, covering the Ozempic, Wegovy and Rybelsus brands and a generic.[2]

The Wegovy tablets are a separate application, with an original approval date recorded as 20251222, adding an oral weight-management form to the injectables.[2]

Drugs@FDA lists Wegovy HD, a 7.2 mg/0.75 mL pen, as a separate Wegovy brand entry.[2]

Drugs@FDA also lists a generic semaglutide injection from Apotex in 3 strengths, with marketing status None (Tentative Approval), so it is not yet a marketable product.[2]

Compounding: the 2026 moves

FDA announced on February 06, 2026 that it intends to restrict GLP-1 active pharmaceutical ingredients going into non-approved compounded drugs marketed as alternatives to approved drugs.[10]

On April 30, 2026 FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound them from bulk substances.[11]

The comment docket for that proposal was open until June 29, 2026, after which FDA said it would consider comments before making a final determination, so the exclusion is a proposal until finalized.[11]

Earlier FDA guidance states that semaglutide and tirzepatide do not appear on the 503B bulks list or on the drug shortage list.[12]

Enforcement and sport

The August warning letters list semaglutide alongside retatrutide, SS-31, PT-141 and tesamorelin sold by research-use-only sites.[13]

WADA's S0 catch-all covers only substances with no current approval anywhere, and semaglutide is FDA-approved, so S0 is not the relevant provision.[1]

Common questions

Is semaglutide FDA approved?

Yes. Drugs@FDA lists approved semaglutide injections and tablets from Novo.[2]

Is Semaglutide legal to buy?

As an approved drug it requires a prescription in the US. Products sold online as research chemicals "not for human use" are not the approved drug.

Is Semaglutide banned by WADA?

No. GLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it.

Is Ozempic FDA approved?

Yes. Ozempic is listed under its own application with several strengths and a 20171205 original approval date.[2]

Is Wegovy FDA approved?

Yes. Wegovy is approved as injections, and the label’s indication includes lowering the risk of major cardiovascular events alongside weight reduction.[14]

Is compounded semaglutide legal?

FDA's statement is that unapproved compounded versions do not undergo its review for safety, effectiveness and quality before they are marketed.[15]

How can you tell if semaglutide is the real FDA-approved version?

FDA lists red flags in telehealth offers: claims that a compounded drug is the same as an FDA-approved drug, and deep discounts or prices that seem too good to be true.[15]

More on Semaglutide

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2United States: Approved by FDA as Ozempic (2017), Rybelsus (2019) and Wegovy (2021), semaglutide, Novo Nordisk. Ozempic is indicated for type 2 diabetes; Wegovy for weight reduction and cardiovascular risk reduction (see label quotes). Drugs@FDA also lists a tentatively approved generic semaglutide application (Apotex, 7 Apr 2026).U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  3. 3United Kingdom: Listed on emc as Ozempic, Wegovy and Rybelsus (semaglutide), Novo Nordisk Limited.Electronic Medicines Compendium (UK) · 2026medicines.org.ukAccessed 2 Oct 2026
  4. 4Canada: Health Canada DPD lists Wegovy and Rybelsus (semaglutide) as Marketed; Ozempic is also listed.Health Canada · 2026health-products.canada.caAccessed 2 Oct 2026
  5. 5Australia: Registered in the ARTG (TGA search for "semaglutide" on 2 Oct 2026).Therapeutic Goods Administration (Australia) · 2026tga.gov.auAccessed 2 Oct 2026
  6. 6European Union: Centrally authorised in the EU as Wegovy, Ozempic and Rybelsus (semaglutide).European Medicines Agency · 2026ema.europa.euAccessed 2 Oct 2026
  7. 7FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  8. 8FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
  9. 9Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
  10. 10Official web pageOfficial web page · web page
  11. 11Official web pageOfficial web page · web page
  12. 12Official web pageOfficial web page · web page
  13. 13Official web pageOfficial web page · web page
  14. 14WEGOVY prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  15. 15Official web pageOfficial web page · web page

Found an error? Report a correction.